Clinical Study of Nasopharyngeal Carcinoma Treated by Helical Tomotherapy in China : 5-Year Outcomes

Abstract EN

Background.

To evaluate the outcomes of nasopharyngeal carcinoma (NPC) patients treated with helical tomotherapy (HT).

Methods.

Between September 2007 and August 2012, 190 newly diagnosed NPC patients were treated with HT.

Thirty-one patients were treated with radiation therapy as single modality, 129 with additional cisplatin-based chemotherapy with or without anti-EGFR monoclonal antibody therapy, and 30 with concurrent anti-EGFR monoclonal antibody therapy.

Results.

Acute radiation related side effects were mainly grade 1 or 2.

Grade 3 and greater toxicities were rarely noted.

The median followup was 32 (3–38) months.

The local relapse-free survival (LRFS), nodal relapse-free survival (NRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were 96.1%, 98.2%, 92.0%, and 86.3%, respectively, at 3 years.

Cox multivariate regression analysis showed that age and T stage were independent predictors for 3-year OS.

Conclusions.

Helical tomotherapy for NPC patients achieved excellent 3-year locoregional control, distant metastasis-free survival, and overall survival, with relatively minor acute and late toxicities.

Age and T stage were the main prognosis factors.